Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EGRX logo EGRX
Upturn stock ratingUpturn stock rating
EGRX logo

Eagle Pharmaceuticals Inc (EGRX)

Upturn stock ratingUpturn stock rating
$2.9
Last Close (24-hour delay)
Profit since last BUY56.76%
upturn advisory
Consider higher Upturn Star rating
BUY since 58 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: EGRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $17

1 Year Target Price $17

Analysts Price Target For last 52 week
$17Target price
Low$0
Current$2.9
high$6.37

Analysis of Past Performance

Type Stock
Historic Profit -27.13%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.58M USD
Price to earnings Ratio 3.41
1Y Target Price 17
Price to earnings Ratio 3.41
1Y Target Price 17
Volume (30-day avg) 1
Beta 0.62
52 Weeks Range 0.00 - 6.37
Updated Date 06/30/2025
52 Weeks Range 0.00 - 6.37
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.85

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 4.64%
Operating Margin (TTM) 15.94%

Management Effectiveness

Return on Assets (TTM) 6.63%
Return on Equity (TTM) 4.88%

Valuation

Trailing PE 3.41
Forward PE 11.34
Enterprise Value 93839858
Price to Sales(TTM) 0.15
Enterprise Value 93839858
Price to Sales(TTM) 0.15
Enterprise Value to Revenue 0.36
Enterprise Value to EBITDA 1.68
Shares Outstanding 12958200
Shares Floating 9305684
Shares Outstanding 12958200
Shares Floating 9305684
Percent Insiders 11.64
Percent Institutions 50.09

Analyst Ratings

Rating 1
Target Price 17
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Eagle Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Eagle Pharmaceuticals Inc. was founded in 2007. It focuses on developing and commercializing injectable products, primarily in the areas of critical care and oncology.

business area logo Core Business Areas

  • Proprietary Products: Development and commercialization of branded pharmaceutical products.
  • Royalty and Contract Revenue: Receiving royalties and revenue from licensing agreements and contract manufacturing.

leadership logo Leadership and Structure

The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • BENDEKA (bendamustine hydrochloride injection): A rapid infusion formulation of bendamustine, used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Competitors include generic bendamustine manufacturers.
  • PEMFEXY (pemetrexed injection): A liquid, ready-to-dilute version of pemetrexed, a chemotherapy drug used to treat certain types of lung cancer and mesothelioma. Eagle Pharma has secured an exclusive license and royalty agreement for PEMFEXY. Competitors include generic pemetrexed manufacturers.
  • BARDAFIL (deferoxamine mesylate for injection): Ready-to-use deferoxamine mesylate for injection. Competitors include generic deferoxamine mesylate manufacturers.
  • LANDAU (oxaliplatin injection): Ready-to-dilute oxaliplatin injection. Competitors include generic oxaliplatin manufacturers.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition from both branded and generic drug manufacturers. The injectables market is a significant component, driven by oncology and critical care needs.

Positioning

Eagle Pharmaceuticals focuses on developing injectable products with improved formulations or delivery methods, aiming to provide clinical advantages and capture market share in niche therapeutic areas. The company aims to differentiate through faster administration, reduced side effects, or improved stability.

Total Addressable Market (TAM)

The injectables market is multi-billion USD. Eagle Pharmaceuticals focuses on specific segments within this TAM, aiming to capture a portion of the market with its differentiated products.

Upturn SWOT Analysis

Strengths

  • Differentiated product formulations
  • Focus on niche therapeutic areas
  • Established partnerships and licensing agreements
  • Experienced management team

Weaknesses

  • Reliance on a limited number of products
  • Dependence on third-party manufacturers
  • Exposure to generic competition
  • Small Market Cap

Opportunities

  • Expansion into new therapeutic areas
  • Acquisition of complementary products or technologies
  • Strategic partnerships for international expansion
  • Regulatory approvals for new formulations

Threats

  • Increased generic competition
  • Patent challenges
  • Changes in regulatory requirements
  • Pricing pressures from payers

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • MYL
  • PFE
  • VRX

Competitive Landscape

Eagle Pharmaceuticals competes with both branded and generic pharmaceutical companies. Its competitive advantage lies in its differentiated product formulations and focus on niche therapeutic areas. However, it faces challenges from larger companies with greater resources and broader product portfolios.

Growth Trajectory and Initiatives

Historical Growth: Requires access to historical financial data to analyze the company's growth trends.

Future Projections: Requires access to analyst reports and company guidance to provide projections for future growth.

Recent Initiatives: Requires access to company press releases and SEC filings to highlight recent strategic initiatives.

Summary

Eagle Pharmaceuticals is a niche pharmaceutical company focusing on injectable products with differentiated formulations. Its strength lies in its innovative products and targeted therapeutic areas, however, its reliance on a few products and exposure to generic competition present challenges. Future growth depends on successful product development, strategic partnerships, and navigating the competitive landscape. Financial stability and future profitability depends on its ability to maintain margins and expand its product pipeline.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Financial data needs to be obtained from latest quarterly and annual reports.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Eagle Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Woodcliff Lake, NJ, United States
IPO Launch date 2014-02-12
CEO -
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 134
Full time employees 134

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.